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Summary 
Background Co-trimoxazole prophylaxis can reduce mortality from untreated HIV infection in Africa; whether beneﬁ ts 
occur alongside combination antiretroviral therapy (ART) is unclear. We estimated the eﬀ ect of prophylaxis after ART 
initiation in adults. 
Methods Participants in our observational analysis were from the DART randomised trial of management strategies 
in HIV-infected, symptomatic, previously untreated African adults starting triple-drug ART with CD4 counts lower 
than 200 cells per μL. Co-trimoxazole prophylaxis was not routinely used or randomly allocated, but was variably 
prescribed by clinicians. We estimated eﬀ ects on clinical outcomes, CD4 cell count, and body-mass index (BMI) using 
marginal structural models to adjust for time-dependent confounding by indication. DART was registered, number 
ISRCTN13968779.
Findings 3179 participants contributed 14 214 years of follow-up (8128 [57%] person-years on co-trimoxazole). 
Time-dependent predictors of co-trimoxazole use were current CD4 cell count, haemoglobin concentration, BMI, 
and previous WHO stage 3 or 4 events on ART. Present prophylaxis signiﬁ cantly reduced mortality (odds ratio 
0·65, 95% CI 0·50–0·85; p=0·001). Mortality risk reduction on ART was substantial to 12 weeks (0·41, 0·27–0·65), 
sustained from 12–72 weeks (0·56, 0·37–0·86), but not evident subsequently (0·96, 0·63–1·45; heterogeneity 
p=0·02). Variation in mortality reduction was not accounted for by time on co-trimoxazole or current CD4 cell 
count. Prophylaxis reduced frequency of malaria (0·74, 0·63–0·88; p=0·0005), an eﬀ ect that was maintained with 
time, but we observed no eﬀ ect on new WHO stage 4 events (0·86, 0·69–1·07; p=0·17), CD4 cell count (diﬀ erence 
vs non-users, –3 cells per μL [–12 to 6]; p=0·50), or BMI (diﬀ erence vs non-users, –0·04 kg/m² [–0·20 to 0·13); 
p=0·68]. 
Interpretation Our results reinforce WHO guidelines and provide strong motivation for provision of co-trimoxazole 
prophylaxis for at least 72 weeks for all adults starting combination ART in Africa. 
Funding UK Medical Research Council, the UK Department for International Development, the Rockefeller 
Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories.
Introduction
Co-trimoxazole (trimethoprim-sulfamethoxazole) is a 
widely available, oﬀ -patent, low-cost antibiotic that is 
used in resource-limited settings to treat and prevent 
community-acquired infections. Although not 
recommended as malaria prophylaxis, similar to 
pyrimethamine-sulfadoxine, it also has antimalarial 
activity.1 In HIV infection, it is highly eﬀ ective for 
treatment of and prophylaxis against Pneumocystis 
jirovecii pneumonia,2 Toxoplasma gondii,3 and Isospora 
belli.4,5 Results of clinical trials and observational studies 
in HIV-infected, combination antiretroviral therapy 
(ART)-naive adults and children across Africa have 
shown that co-trimoxazole prophylaxis reduces 
mortality, morbidity, and hospital admissions,4–10 even 
in areas of high background bacterial resistance. 
WHO guidelines recommend that co-trimoxazole 
prophylaxis is given to all symptomatic adults with 
CD4 counts lower than 350 cells per μL in resource-
limited settings.11 
Routinely used with ART in high-income countries, co-
trimoxazole prophylaxis is usually discontinued when 
CD4 count exceeds 200 cells per μL because the primary 
goal is prevention of P jirovecii pneumonia.12,13 Despite 
WHO guidelines, co-trimoxazole has been poorly used 
with ART in resource-limited settings; and data for its bene-
ﬁ ts (in addition to those of ART), toxic eﬀ ects, and eﬀ ect on 
ART adherence are scarce. In only one large retro spec tive 
cohort study in Malawi, investigators reported a 41% 
reduction in mortality during the ﬁ rst 6 months after ART 
initiation in clinics providing co-trimoxazole prophylaxis.14
Participants in the Development of Anti-Retroviral 
Therapy in Africa (DART) trial15 had variable exposure to 
co-trimoxazole; prophylaxis was neither routine nor 
randomised, but was initiated or continued at discretion 
of the treating clinician. We aimed to estimate the causal 
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eﬀ ect of co-trimoxazole prophylaxis on survival, WHO 
stage 3 and 4 events, malaria, CD4 cell count, body-mass 
index (BMI), and haematological indices in adults after 
initiation of ART. 
Methods 
Study design and participants
In our observational analysis, we used data from the 
randomised DART trial15 comparing laboratory plus 
clinical monitoring (LCM) with clinically driven 
monitoring (CDM) of ART, undertaken in two clinical 
centres in Uganda (the Medical Research Council/
Uganda Virus Research Institute Uganda Research Unit 
on AIDS, Entebbe; and the Joint Clinical Research 
Centre, Kampala, with a satellite clinic at the Infectious 
Diseases Institute, Mulago), and one centre in Zimbabwe 
(University of Zimbabwe, Harare). Participants were 
symptomatic (WHO stage 2–4) HIV-infected adults (≥18 
years) with CD4 counts lower than 200 cells per μL who 
reported no previous ART apart from to prevent mother-
to-child transmission.
At enrolment all participants started triple-drug 
combination ART (coformulated zidovudine-lamivudine 
[GlaxoSmithKline, Ware, UK] plus tenofovir disoproxil 
fumarate [Gilead Science, Foster City, CA, USA], abacavir 
[GlaxoSmithKline, Ware, UK], or nevirapine [Boehringer 
Ingelheim, Ingelheim, Germany]). Participants attended 
study clinics every 4 weeks, when nurses administered 
standard symptom and adherence checklists and 
dispensed prescriptions. Participants could be referred to 
a doctor at any time and were asked to return to the clinic 
if they felt unwell between visits. All participants saw a 
doctor and had a full blood count, lymphocyte subsets, 
and liver and renal function tests at weeks 4 and 12, then 
every 12 weeks. All results for LCM participants were 
returned to clinicians, whereas for CDM participants, 
haematology and biochemistry results were returned 
only if requested for clinical reasons or if grade 4 toxic 
eﬀ ects were reported (protocol safety criteria, grades 
deﬁ ned in protocol according to minor modiﬁ cations of 
the AIDS Clinical Trials Group criteria16) and lymphocyte 
subsets were never returned. 
Co-trimoxazole was taken once daily (800 mg 
sulfamethoxazole, 160 mg trimethoprim). Use of other 
non-ART drugs (prescription and indication) and 
malaria episodes (clinical or microscopic diagnosis) 
were recorded at every doctor visit. Structured 
summaries for all reported WHO 2003 stage 4 events17 
and deaths were reviewed by an endpoint review 
committee, who were masked to monitoring strategy 
and CD4 cell count. 
137 (4%) participants who entered a non-randomised 
pilot study of structured treatment interruptions were 
excluded. A further 813 participants with CD4 counts of 
300 cells per μL or higher were randomly allocated at 
52 or 76 weeks to interrupted treatment cycles of 
12 weeks on and 12 weeks oﬀ  ART or to stay on 
continuous therapy.18 We excluded follow-up after 
substudy randomisation for interrupted treatment 
participants and upweighted it in those receiving 
continuous treatment (ie, continuous treatment 
participants were given sampling weights (of roughly 
two) so that they represented interrupted-treatment 
participants after censoring, in addition to themselves), 
assuming comparability of treatment groups at substudy 
randomisation.
Oﬀ  co-trimoxazole 
prophylaxis at ART 
initiation (n=1220)*
On co-trimoxazole 
prophylaxis at ART 
initiation (n=1959)*
All participants 
(n=3179)
Centre
A 550 (57%) 414 (43%) 964 (30%)
B 428 (45%) 514 (55%) 942 (30%)
C 208 (21%) 771 (79%) 979 (31%)
D (satellite clinic) 34 (12%) 260 (88%) 294 (9%)
Randomly allocated to
Laboratory and clinical monitoring 611 (39%) 969 (61%) 1580 (50%)
Clinically driven monitoring 609 (38%) 990 (62%) 1599 (50%)
Randomly allocated in
2003 518 (29%) 1244 (71%) 1762 (55%)
2004 702 (50%) 715 (50%) 1417 (45%)
Age (years) 37 (32–42) 37 (32–42) 37 (32–42)
Men 444 (40%) 678 (60%) 1122 (35%)
Women 776 (38%) 1281 (62%) 2057 (65%)
WHO disease stage
2 263 (41%) 382 (59%) 645 (20%)
3 715 (40%) 1079 (60%) 1794 (56%)
4 242 (33%) 498 (67%) 740 (23%)
WHO stage 3 or 4 event17 <4 weeks before ART initiation
No 792 (38%) 1307 (62%) 2099 (66%)
Yes 428 (40%) 652 (60%) 1080 (34%)
CD4 count (cells per μL) 83 (29–136) 82 (30–137) 83 (29–137)
Haemoglobin (g/L) 114 (103–127) 114 (102–126) 114 (103–127)
Body-mass index
Median 21 (19–23) 21 (19–24) 21 (19–24)
≤18·5 kg/m2 261 (43%) 340 (57%) 601 (19%)
>18·5 kg/m2 959 (37%) 1619 (63%) 2578 (81%)
Initial ART
Combivir plus tenofovir 778 (33%) 1554 (67%) 2332 (73%)
Combivir plus abacavir 173 (58%) 127 (42%) 300 (9%)
Combivir plus nevirapine 269 (49%) 278 (51%) 547 (17%)
Taking co-trimoxazole prophylaxis at screening†
No 1220 (61%) 794 (39%) 2014 (63%)
Yes 0 (0%) 1165 (100%) 1165 (37%)
Weeks of use at screening (in users)† ·· 12 (3–33) 12 (3–33)
Data are n (%) or median (IQR). 137 of 3316 DART participants randomly allocated to the monitoring strategies who 
participated in a non-randomised substudy of structured treatment interruptions at week 28 are not included in this 
analysis. Predictors of use of co-trimoxazole prophylaxis at ART initiation varied by centre. ART=antiretroviral therapy. 
*All percentages in on and oﬀ  co-trimoxazole columns are proportions of the row total in the all participants column. 
†Participants were screened for entry into the Development of AntiRetroviral Therapy in Africa15 trial a median 14 days 
(IQR 13–16) before entry. 
Table 1: Characteristics of included participants at ART initiation
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Patients gave written consent for screening and, if 
eligible, enrolment. DART was approved by research 
ethics committees in Uganda, Zimbabwe, and the UK.
Statistical analysis
All analyses were done with Stata (version 10.0). We used 
marginal structural models19 to estimate causal eﬀ ects of 
co-trimoxazole prophylaxis on outcomes. These models 
adjusted for time-dependent covariates with inverse-
probability treatment weights and were appropriate in the 
presence of time-dependent covariates (such as BMI) that 
might be associated with both prescription of co-trimoxazole 
and outcomes (time-dependent confounders), and could 
also be aﬀ ected by past co-trimoxazole prophylaxis 
(webappendix). 
DART was registered, number ISRCTN13968779.
Role of the funding source
The sponsor (UK Medical Research Council) and other 
funders had no direct role in study design, data 
collection, analysis, or interpretation, or writing of the 
report, either for this observational analysis or the 
original randomised trial. The corresponding author 
had full access to all data.
Results
3316 eligible participants were enrolled in DART15 
between Jan 15, 2003, and Oct 24, 2004. We excluded 
137 (4%) participants who entered a non-randomised 
pilot study of structured treatment interruptions 
28 weeks after ART initiation. Characteristics of the 
3179 participants included are representative of 
participants in ART programmes in Africa (table 1); all 
participants had CD4 counts lower than 200 cells per μL 
before starting therapy. Length of follow-up was median 
4·9 years (IQR 4·5–5·3) with only 198 (6%) of 
3179 participants last seen alive more than 4 months 
before Dec 31, 2008 (end of follow-up). Completeness 
of 4-week nurse (98%) and 12-week doctor (99%) visits 
was very high. 
Death* (n=326¶) New WHO stage 4 events*† 
(n=515¶)
 New or recurrent WHO stage 3 or 4 
events*‡ (n=1295¶)
New or recurrent malaria*§ 
(n=1170¶)
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Overall eﬀ ect||
Not present user 1·0 ·· 1·0 ·· 1·0 ·· 1·0 ··
Present user 0·65 (0·50–0·85) 0·001 0·86 (0·69–1·07) 0·17 0·85 (0·74–0·98) 0·02 0·74 (0·63–0·88) 0·0005
Pattern of co-trimoxazole use
Never used 1·0 ·· 1·0 ·· 1·0 ·· 1·0 ··
Not present user**
Used >12 weeks ago 1·04 (0·66–1·62) 0·88 0·58 (0·39–0·85) 0·006 1·03 (0·80–1·31) 0·84 1·23 (1·01–1·49) 0·04
Used in past 12 weeks 0·64 (0·35–1·16) 0·14 0·80 (0·37–1·70) 0·56 0·79 (0·55–1·12) 0·18 0·83 (0·62–1·10) 0·19
Present user††
On for 1–12 weeks 0·46 (0·30–0·71) 0·0005 0·81 (0·60–1·09) 0·16 0·90 (0·75–1·07) 0·23 0·74 (0·60–0·92) 0·007
On for 12–24 weeks 0·68 (0·42–1·10) 0·12 0·70 (0·45–1·09) 0·12 0·89 (0·68–1·17) 0·41 0·80 (0·57–1·13) 0·21
On for >24 weeks 0·74 (0·48–1·12) 0·15 0·63 (0·45–0·89) 0·008 0·77 (0·61–0·97) 0·03 0·80 (0·62–1·02) 0·08
Time on ART
Not present user 1·0 ·· 1·0 ·· 1·0 ·· 1·0 ··
Present user‡‡
0–12 weeks on ART 0·41 (0·27–0·65) 0·0001 0·74 (0·53–1·02) 0·07 0·86 (0·71–1·05) 0·14 0·76 (0·60–0·98) 0·03
12–48 weeks on ART 0·59 (0·37–0·95) 0·03 0·83 (0·53–1·32) 0·44 0·96 (0·74–1·25) 0·78 0·78 (0·60–1·02) 0·07
48–72 weeks on ART 0·47 (0·20–1·08) 0·08 0·71 (0·37–1·39) 0·33 0·92 (0·63–1·34) 0·66 0·50 (0·33–0·74) 0·001
72–96 weeks on ART 1·28 (0·54–3·03) 0·57 1·10 (0·49–2·46) 0·82 0·92 (0·56–1·51) 0·74 0·84 (0·52–1·34) 0·46
>96 weeks on ART 0·89 (0·57–1·40) 0·61 0·98 (0·67–1·43) 0·91 0·71 (0·54–0·92) 0·01 0·76 (0·55–1·03) 0·08
OR=odds ratio. ART=antiretroviral therapy. *Risk of ﬁ rst event or episode estimated from weighted logistic regression models adjusting for length of time on ART with cubic splines, centre, randomised 
monitoring group, randomisation year, age, sex, WHO stage, and ART prescription at randomisation together with baseline and time-varying values of CD4 cell count, haemoglobin concentration, body-mass 
index, a WHO stage 3 or 4 event in the previous 4 weeks or since randomisation, and randomisation into a structured treatment interruption (STI) substudy (never, to continuous therapy [CT]). †Oesophageal 
candidosis (159), cryptococcosis (115), extrapulmonary tuberculosis (108), cryptosporidia (25), Pneumocystis jirovecii pneumomia (22), chronic mucocutaneous herpes simplex (22), HIV wasting (17), Kaposi’s 
sarcoma (15), toxoplasmosis (13), other (ten or fewer of any event) (19). ‡Severe bacterial infection (365, including pneumonia [280, single occurrences as per WHO 2003 guidelines17], septicaemia [29], 
pyomyositis [17], meningitis [six], other [33]), oral candida (281), weight loss of more than 10% (133), oesophageal candidosis (115), pulmonary tuberculosis (98), cryptococcosis (87), extrapulmonary 
tuberculosis (75), oral hairy leukoplakia (36), other (105; ≤20 of any event). §Excluding participants from Harare. ¶Eight deaths, 20 WHO 4 events, 48 WHO stage 3 or 4 events, and 78 malaria episodes 
occurred after randomisation to CT within the Development of AntiRetroviral Therapy in Africa15 STI/CT substudy and were upweighted in analyses. ||p values for test of heterogeneity between centres were 
0·85, 0·37, 0·07, and 0·68, for death, stage 4 events, stage 3 or 4 events, and malaria, respectively. **p values for test of heterogeneity in eﬀ ect of co-trimoxazole prophylaxis between never users, used more 
than 12 weeks ago, and used in the past 12 weeks were 0·28, 0·02, 0·36, and 0·02. ††p values for test of heterogeneity in eﬀ ect of co-trimoxazole prophylaxis between present users by duration of consecutive 
use (1–12, 12–24, >24 weeks) were 0·21, 0·46, 0·42, and 0·87. ‡‡p values for test of heterogeneity between time periods were 0·06, 0·76, 0·50, and 0·31.
Table 2: Eﬀ ect of co-trimoxazole prophylaxis on death, new WHO stage 4 events, new or recurrent WHO stage 3 or 4 events, and malaria 
See Online for webappendix
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Participants had variable exposure to co-trimoxazole; 
prophylaxis was never prescribed during follow-up for 
324 (10%) participants, 1959 (62%) were taking it at ART 
initiation, and 896 (28%) started while on ART, with 
median 3·5 years (0·9–4·5) total use post-ART in those 
ever starting. Use at ART initiation varied with centre, 
year of randomisation, and initial combination treatment. 
Of 368 participants who died before end of follow-up, 
only 25 (7%) did not have complete co-trimoxazole history 
before death and were censored at their last clinic visit. 
8128 (57%) person-years of follow-up were spent on co-
trimoxazole. Use of prophylaxis diﬀ ered substantially 
between the four centres (15%, 72%, 72%, 79%). Only 
105 (<1%) person-years of follow-up were spent oﬀ  ART. 
Reported ART adherence was high both in participants 
currently on and oﬀ  co-trimoxazole, with no missed 
doses in the past 4 weeks reported at 5234 (83%) and 
2426 (78%) visits, respectively, in the ﬁ rst 12 weeks, at 
19 688 (93%) and 19 415 (87%) visits in weeks 12–72, and 
at 65 669 (93%) and 39 965 (91%) visits at more than 
72 weeks of ART, excluding visits after randomisation to 
structured treatment interruptions.
Exclusion of follow-up after randomisation to 
structured treatment interruptions and upweighting of 
follow-up after continuous treatment gave 326 deaths 
(including eight upweighted) in 14 214 total person-years 
(2·3 per 100 person-years) included in analyses. 85 (26%) 
deaths occurred within 12 weeks of ART initiation 
(11·8 per 100 person-years). Present co-trimoxazole pro-
phylaxis halved mortality in the ﬁ rst 12 weeks on ART, 
with no variation between participants on prophylaxis 
before screening (odds ratio [OR] 0·52, 95% CI 
0·30–0·92, adjusted for baseline factors; p=0·02) versus 
those starting prophylaxis at the same time as ART 
(0·46, 0·25–0·84; p=0·01; heterogeneity p=0·69) or of 
variation between centres (heterogeneity p=0·35). 
Overall, using unweighted logistic regression and 
adjusting for baseline factors, but not controlling for 
time-dependent con founders, we showed that present 
co-trimoxazole use was associated with a 27% mortality 
reduction (0·73, 0·56–0·96; p=0·02; between-centre 
heterogeneity p=0·07). 
As expected, mortality was higher in participants with 
low current CD4 cell count, haemoglobin concentration, 
or BMI, or with a WHO stage 3 or 4 event in the previous 
4 weeks or any stage 3 or 4 event since randomisation 
(data not shown). These factors were also associated with 
increased probability of co-trimoxazole use, although 
extent of association varied between centres (data not 
shown). When we adjusted for these time-dependent 
predictors and randomisation to continuous treatment as 
factors within a regression model for mortality, the 
estimated OR for co-trimoxazole use was 0·62 (0·48–0·80; 
p=0·0002; between-centre heterogeneity p=0·50). 
In a marginal structural model with inverse-probability 
treatment weights to control for time-dependent 
confounders, present prophylaxis reduced overall mortality 
risk by 35% (OR vs no present use 0·65, 0·50–0·85, 
p=0·001; table 2, ﬁ gure). Beneﬁ t did not diﬀ er with 
randomised monitoring group (heterogeneity p=0·24). 
Furthermore, mortality risks did not diﬀ er between 
participants who had stopped prophylaxis and never users, 
and beneﬁ t did not vary with increasing time on co-
trimoxazole in present users on ART (table 2, ﬁ gure). 
Figure: Eﬀ ect of co-trimoxazole prophylaxis with ART from weighted models
(A) Clinical outcomes on ART. (B) Predicted survival on ART*. ART=antiretroviral therapy. 
CTX=co-trimoxazole. OR=odds ratio. *Assumes co-trimoxazole prophylaxis has diﬀ erent eﬀ ects in weeks 0–72 
(OR 0·49) and after 72 weeks (OR 0·96) on ART. Risks were estimated for a woman aged 30–40 years starting ART 
(lamivudine-zidovudine plus tenofovir) in 2003 with WHO stage 3 disease, haemoglobin 115 g/L, BMI >21 kg/m2, 
no WHO stage 3 or 4 event in the 4 weeks before starting ART, and CD4 count 15 or 150 cells per μL.
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Beneﬁ t of present co-trimoxazole prophylaxis did, 
however, vary signiﬁ cantly with time on ART 
(heterogeneity p=0·04 in a ﬂ exible model for time on 
ART with cubic splines20), falling from a 58% reduction 
in the ﬁ rst 4 weeks on ART to a 5% reduction in 
weeks 68–72 (every additional 4 weeks on ART to 
72 weeks increased estimated OR by 1·05 [1·01–1·09]; 
p=0·03), with no eﬀ ect subsequently (p=0·67). When we 
categorised time on ART to show this variation, mortality 
reduction was greatest in the ﬁ rst 12 weeks of treatment, 
sustained from 12–72 weeks, but not evident subsequently 
(heterogeneity p=0·02; ﬁ gure). Adjustment for time on 
ART and time on co-trimoxazole simultaneously in 
present users showed that eﬀ ect of time on ART was not 
confounded by duration of prophylaxis; similar mortality 
risk reductions were reported in the ﬁ rst 72 weeks on 
ART in participants on co-trimoxazole for fewer than 
24 consecutive weeks (OR 0·50, 0·34–0·73) and more 
than 24 consecutive weeks (0·48, 0·28–0·83), and we 
noted no reduction in mortality after 72 weeks on ART 
in either group (0·91 [0·47–1·77], heterogeneity before vs 
after 72 weeks, p=0·12; OR 0·96 [0·63–1·47], 
heterogeneity before vs after 72 weeks, p=0·05 
respectively). Estimated average 5-year survival in DART 
participants starting ART with CD4 counts of 15 or 
150 cells per μL increased by 5% and 2%, respectively, 
with co-trimoxazole prophylaxis (ﬁ gure).
We estimated eﬀ ects of prophylaxis on mortality from 
primary, secondary, or tertiary causes regarded as 
potentially preventable by co-trimoxazole (92 deaths: 
septicaemia [39], pneumonia [16], severe brain syndrome 
as deﬁ ned by the endpoint review committee [generally 
representing undiagnosed toxoplasmosis; 13], non-
cryptococcal meningitis [8], diarrhoea [5], malaria [4], 
P jirovecii pneumonia [2], acute febrile event [2], 
toxoplasmosis [1], chronic pulmonary disease [1], or 
visceral abscess [1]), versus other causes (179 deaths: 
cryptococcus [31], tuberculosis [26], lymphoma or 
Kaposi’s sarcoma [16], other [106]) versus unknown 
cause (55), separately. Present prophylaxis reduced risk 
of deaths from causes regarded as potentially 
preventable by co-trimoxazole by 21% (OR 0·79, 
0·49–1·27), other deaths by 35% (0·65, 0·45–0·93), and 
unknown deaths by 48% (0·52, 0·27–1·00). In the ﬁ rst 
72 weeks on ART, 66 (35%) deaths were from causes 
potentially preventable by co-trimoxazole compared 
with 92 (49%) due to other causes and 30 (16%) 
unknown; with similar mortality risk reductions 
associated with co-trimoxazole prophylaxis (OR 0·64 
[0·37–1·10], 0·48 [0·30–0·77], and 0·29 [0·12–0·73] 
respectively). After 72 weeks, 26 (19%) deaths were from 
causes potentially preventable by co-trimoxazole, 
87 (63%) were due to other causes, and 25 (18%) were of 
unknown cause; again, we found no diﬀ erence in 
co-trimoxazole eﬀ ect (OR 1·56 [0·59–4·14], 0·89 
[0·53–1·50], and 0·93 [0·38–2·27], respectively). 
All participants began ART with a CD4 count lower 
than 200 cells per μL; 2576 (62%) person-years of follow-
up in the ﬁ rst 72 weeks and 2678 (27%) subsequently 
were spent with most recent CD4 count lower than 
200 cells per μL. In the ﬁ rst 72 weeks on ART, we 
estimated similar mortality reductions in participants 
with current CD4 counts lower than 200 cells per μL 
and 200 cells per μL or more on co-trimoxazole 
prophylaxis (ﬁ gure). After 72 weeks on ART we noted no 
beneﬁ t of present co-trimoxazole prophylaxis in 
participants with current CD4 counts lower than 
200 cells per μL or 200 cells per μL or more (ﬁ gure). 
Results were similar for deaths from causes regarded as 
potentially preventable by co-trimoxazole and for deaths 
from other causes. Alternative models including an 
additional CD4 count category of lower than 100 cells 
per μL (table 3), more than 350 cells per μL, or allowing 
for a non-linear eﬀ ect of CD4 cell count also provided 
no evidence for variation in eﬀ ect of co-trimoxazole 
prophylaxis with current CD4 cell count. 
0–72 weeks on ART >72 weeks on ART
Deaths/PY* Rate OR (95% CI)† p value Deaths/PY* Rate OR (95% CI)† p value
Current CD4 count 0–99 cells per μL‡
Not present user 71/398 17·8 ·· ·· 21/235 8·92 ·· ··
Present user 60/563 10·7 0·48 (0·33–0·69) 0·0001 43/474 9·07 0·87 (0·55–1·39) 0·57
Current CD4 count 100–199 cells per μL‡
Not present user 22/732 3·01 ·· ·· 10/643 1·56 ·· ··
Present user 20/884 2·26 0·52 (0·30–0·92) 0·03 16/1330 1·20 0·95 (0·52–1·74) 0·86
Current CD4 count ≥200 cells per μL‡
Not present user 12/881 1·36 ·· ·· 20/3177 0·63 ·· ··
Present user 3/695 0·43 0·56 (0·29–1·07) 0·08 36/4202 0·86 1·01 (0·54–1·89) 0·98
ART=antiretroviral therapy. PY=person-years. OR=odds ratio. *Deaths and person-years were excluded after randomisation to structured treatment interruptions in a 
substudy and upweighted after randomisation to continuous therapy. †OR are relative to no present use of co-trimoxazole prophylaxis and were estimated with history-
adjusted marginal structural models, treating every 12-week follow-up visit as a new baseline, and considering mortality during the next 12 weeks (webappendix p 2). 
‡CD4 cell count at last 12-week follow-up visit. 
Table 3: Eﬀ ect of co-trimoxazole prophylaxis on death by time on ART and current CD4 cell count†
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Oesophageal candidosis, cryptococcosis, and extra-
pulmonary tuberculosis were the most common WHO 
stage 4 events, contributing 159 (31%), 115 (22%), and 108 
(21%) ﬁ rst events, respectively. Other diagnoses were 
individually less common. Only 22 (4%) stage 4 events 
were P jirovecii pneumonia (21 presumptive), of which 
13 of 22 were on co-trimoxazole prophylaxis. We noted 
little evidence for a reduction in ﬁ rst new WHO stage 4 
events after ART initiation with co-trimoxazole (table 2). 
The marginal beneﬁ t seen in past users is probably due to 
chance or incomplete adjustment for confounders in 
those stopping co-trimoxazole, and results of sensitivity 
analyses did not suggest that we had missed any beneﬁ t 
in present users. Results did not diﬀ er when oesophageal 
candidosis was excluded (data not shown). The eﬀ ect of 
present prophylaxis on WHO stage 3 and 4 events, 
including recurrences of previous events as outcomes, 
was signiﬁ cant, but this small eﬀ ect did not vary with 
time on ART (table 2). Heterogeneity existed between 
centres (p=0·02), and we were unable to obtain consistent 
estimates of the eﬀ ect of co-trimoxazole on pneumonia 
alone (which accounted for 280 [22%] ﬁ rst WHO stage 3 
or 4 events) across all four centres, suggesting variable 
diagnostic criteria or remaining unadjusted confounders.
In the ﬁ rst 12 weeks on ART, CD4 cell count increased 
by a median 73 cells per μL (32–128) and BMI by 
0·76 kg/m² (0·00–1·60). Participants taking co-trimoxazole 
did not have greater CD4 cell count or BMI increases than 
did non-users in the ﬁ rst 12 weeks or subsequently 
(table 4); estimated CD4 increases were slightly reduced 
with co-trimoxazole, probably because of some residual 
confounding (diﬀ erence vs non-users –3 cells per μL 
[–12 to 6]; p=0·50). We showed no eﬀ ect of co-trimoxazole 
on haemoglobin or platelet counts, and observed a small 
signiﬁ cant reduction in neutrophil count in participants 
currently on co-trimoxazole after 72 weeks on ART (table 4). 
Only 22 (3%) of 650 serious adverse events during the 
trial were judged to be related to co-trimoxazole (ten 
deﬁ nite or probable, 12 uncertain relation, all 
haematological, rash, or hypersensitivity).
Harare has low malaria transmission. In Uganda, 
1170 (53%) of 2200 participants had at least one malaria 
event, with 2362 events in total (260 upweighted; 
27 per 100 person-years, 1119 [47%] diagnosed by 
microscopy, 1243 [53%] clinical). Present prophylaxis 
was associated with a 26% reduction in risk of ﬁ rst 
new malaria episode in present users (table 2), with 
similar estimates if more than one episode per person 
was included (data not shown) and a weakened eﬀ ect 
when restricted to parasite-positive diagnoses (0·85 
[0·65–1·11]; p=0·23). The reduction in malaria risk 
associated with co-trimoxazole was maintained 
throughout follow-up.
Discussion 
In this large cohort of HIV-infected symptomatic African 
adults starting combination ART with low CD4 cell 
counts, we showed signiﬁ cant reductions in mortality 
and malaria from daily co-trimoxazole prophylaxis in 
addition to beneﬁ ts conferred by ART. Mortality 
reductions were striking in the ﬁ rst 72 weeks of ART, 
with, in particular, early (0–12 weeks) mortality on ART 
being more than halved. The eﬀ ect on malaria in Uganda 
was sustained beyond 72 weeks, consistent with reports 
that co-trimoxazole is an eﬀ ective agent for malaria 
prophylaxis in semi-immune adults.21 
CD4 count (cells per μL) BMI (kg/m²) Haemoglobin (g/L) Neutrophils×10⁹/L Platelets×10⁹/L
Diﬀ erence p value Diﬀ erence p value Diﬀ erence p value Diﬀ erence p value Diﬀ erence p value
Change between weeks 0 and 12*†
Not present user 0 ·· 0 ·· 0 ·· 0 ·· 0 ··
Present user –2 (–8 to 5) 0·60 –0·06 (–0·17 to 0·05) 0·29 0·2 (–1·2 to 1·5) 0·80 –0·04 (–0·11 to 0·02) 0·18 –4·4 (–10·8 to 2·0) 0·18
Change from week 12‡§¶ (overall eﬀ ect)
Not present user 0 ·· 0 ·· 0 ·· 0 ·· 0 ··
Present user –3 (–12 to 6) 0·50 –0·04 (–0·20 to 0·13) 0·68 0·4 (–0·5 to 1·3) 0·38 –0·05 (–0·10 to 0·00) 0·05 2·0 (–2·5 to 6·5) 0·38
By time on ART‡|| 
Not present user 0 ·· 0 ·· 0 ·· 0 ·· 0 ··
Present user
12–72 weeks on ART –13 (–20 to –5) 0·001 –0·10 (–0·27 to 0·07) 0·26 0·1 (–0·9 to 1·1) 0·80 0·02 (–0·03 to 0·07) 0·43 1·6 (–3·0 to 6·3) 0·49
>72 weeks on ART 0·3 (–11 to 11) 0·96 –0·01 (–0·20 to 0·18) 0·89 0·5 (–0·5 to 1·5) 0·32 –0·07 (–0·13 to –0·02) 0·009 2·1 (–2·8 to 7·0) 0·39
Data are eﬀ ect of co-trimoxazole (95% CI). BMI=body-mass index. ART=antiretroviral therapy. *Estimated from unweighted normal regression models adjusting for centre, randomised monitoring group, randomisation 
year, age, sex, WHO stage, and ART prescription at randomisation together with baseline values of CD4 cell count, haemoglobin concentration, BMI, and a WHO stage 3 or 4 event in the 4 weeks before randomisation. For 
platelet and neutrophil outcomes, corresponding baseline values were also adjusted for. †p values for test of heterogeneity between centres were 0·68, 0·56, 0·21, 0·17, and 0·85, for CD4 cell count, BMI, and haemoglobin, 
and neutrophil and platelet concentrations, respectively. ‡Estimated from weighted repeated measures (every 12 weeks) normal regression models adjusting for length of time on ART with cubic splines, baseline 
covariates*, and time-varying values of CD4 cell count, haemoglobin concentration, BMI, WHO stage 3 or 4 event in the previous 4 weeks or since randomisation, and randomisation into a structured treatment interruption 
substudy (never, to continuous therapy). For neutrophil and platelet outcomes, corresponding time-varying values were also adjusted for. §p values for test of heterogeneity between centres were 0·07, 0·47, 0·21, 0·08, and 
0·16. ¶By pattern of use no evidence was found for an eﬀ ect with increasing time on co-trimoxazole prophylaxis or beneﬁ t in past users compared with never users for any of the ﬁ ve outcomes (data not shown). ||p values 
for test of heterogeneity between time periods were 0·01, 0·33, 0·43, 0·0004, and 0·81. 
Table 4: Eﬀ ect of co-trimoxazole prophylaxis on CD4 cell count, body-mass index, and markers of haematological toxic eﬀ ects
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Randomised trials are needed for the highest level of 
evidence,22 but in their absence patients still have to be 
managed according to the best available evidence from 
other studies, particularly those that are large, well done, 
and have clear, plausible, and consistent results. Since 
our study was observational, identiﬁ cation and 
appropriate adjustment for confounders is essential. 
Participants were in a randomised trial of management 
strategies, so the most important clinical and laboratory 
information used by clinicians for participant manage-
ment was obtained systematically and prospect ively, and 
we were able to do several sensitivity analyses using 
diﬀ erent models of inverse-probability treatment weights. 
In addition to the large cohort size, that we had four 
centres was invaluable for testing of these models since 
heterogeneity in eﬀ ect of co-trimoxazole between centres 
suggested that confounders could remain. In models 
presented, results were consistent across centres and 
randomised monitoring strategies. Finally, censoring 
due to loss-to-follow-up was very low, and although we 
adjusted for censoring by using additional weighting, the 
eﬀ ect was small. Since DART participants, who had 
advanced immunodeﬁ ciency and symptomatic disease, 
had similar characteristics to those of most patients 
starting ART in rollout programmes in Africa, our 
ﬁ ndings should be generalisable. Because our study used 
observational data we cannot guarantee that the results 
are free from bias, but with the systematic approaches 
used the possible direction and magnitude of any 
remaining bias are diﬃ  cult to identify. 
The survival beneﬁ t conferred by co-trimoxazole was 
restricted to present use, with no variation in beneﬁ t with 
use at or before enrolment or with increasing time on 
prophylaxis. The roughly 50% mortality risk reduction to 
72 weeks after ART initiation is similar to that reported 
in ART-naive participants in randomised trials in 
resource-limited countries.4,5,7,10 Beyond 72 weeks on ART, 
we observed no mortality beneﬁ ts. One limitation of our 
data was that most present use beyond 72 weeks was in 
individuals on long-term co-trimoxazole, so we cannot 
distinguish between time from ART initiation and 
duration of eﬀ ects of co-trimoxazole use after this point. 
Trials in ART-naive participants have typically had little 
follow-up beyond 72 weeks,4,5,7 although Nunn10 reported 
a waning eﬀ ect of co-trimoxazole prophylaxis with time, 
possibly related to falling adherence, in patients on 
treatment for concurrent tuberculosis. Stopping of co-
trimoxazole prophylaxis after 72 weeks on ART might 
therefore be a reasonable strategy; randomised trials of 
diﬀ erent durations of prophylaxis would inform this 
issue. Although risk of malaria will remain (as for 
exposed adults not infected with HIV/AIDS), malaria in 
semi-immune adults is generally not serious and is non-
fatal, and co-trimoxazole is not the prophylaxis of choice 
against malaria. In DART, absolute risk of death was 
increased at low CD4 cell counts, but we noted no 
variation in mortality risk reductions according to most 
recent CD4 cell count. Results of ART-naive studies have 
shown no evidence for heterogeneity in eﬀ ect of co-
trimoxazole prophylaxis by baseline CD4 cell count on 
severe morbidity5 or mortality.9 
What co-trimoxazole prophylaxis is preventing, apart 
from malaria, is unclear from our data. In two trials of 
ART-naive adults, co-trimoxazole substantially reduced 
deﬁ nitively diagnosed invasive bacterial disease with 
bacteraemia and malaria.4,5 In children, lower respiratory 
tract infections were signiﬁ cantly reduced, but many 
died rapidly and most diagnoses were presumptive,4,23 as 
seen in other non-randomised co-trimoxazole studies in 
African adults. In DART we obtained through structured 
summaries as much data as possible for deaths, which 
were then independently reviewed by an endpoint review 
committee. In 55 (17%) unobserved deaths, no cause 
could be assigned; in the remainder, primary, secondary, 
and tertiary causes were assigned with emphasis on 
conﬁ rmation of WHO 4 events because these were the 
primary endpoint. Although severe bacterial infections 
(as WHO stage 3 events) were systematically solicited 
and reported, they were not always microbiologically 
investigated. Thus, our data for cause of death cannot 
directly inform about mechanism of action, other than 
to note a substantial eﬀ ect of co-trimoxazole prophylaxis 
on other causes, which could have been because of 
secondary sepsis. 
Recurrent pneumonia diagnoses (individually reported 
as stage 3 events) have been reviewed by the endpoint 
review committee, because the revised WHO 2006 
guidelines include two pneumonia episodes within 
6 months as a stage 4 event.24 However, insuﬃ  cient 
events (n=13) were reported for a separate analysis. A 
key conclusion is that HIV studies in sub-Saharan Africa 
should document severe bacterial morbidity carefully, 
especially in patients with WHO stage 3 or 4 events. 
Although results of a recent study25 suggested that almost 
all Mycobacterium tuberculosis isolates might retain in-
vitro sensitivity to co-trimoxazole, we showed no evidence 
of an eﬀ ect on pulmonary or extrapulmonary 
tuberculosis, similar to other WHO stage 3 or 4 events 
(data not shown).
Even if co-trimoxazole prophylaxis acts by partly or 
mainly reducing risk of mortality due to bacterial 
infections, why this mechanism should translate into 
mortality beneﬁ ts before but not after 72 weeks is unclear. 
In particular, although one could postulate that severity of 
bacterial infections falls with increasing immune 
restoration, we did not show any variation in eﬀ ect of co-
trimoxazole by current CD4 cell count, and speciﬁ cally no 
eﬀ ect on deaths from causes regarded as potentially 
preventable by co-trimoxazole or other deaths in 
participants with low CD4 cell counts after 72 weeks. An 
alternative explanation, lent support by the absence of 
eﬀ ect of prophylaxis on HIV-related disease progression 
and CD4 cell counts, is that although co-trimoxazole does 
not prevent HIV-related events, it might reduce mortality 
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from them, irrespective of CD4 cell count. However, this 
explanation does not account for why the eﬀ ect might 
occur before but not after 72 weeks from ART initiation. 
One hypothesis is that co-trimoxazole lowers bacterial 
load in the gut, thus reducing microbial translocation of 
bacterial lipopolysaccharides from the gastrointestinal 
tract into the bloodstream. Increased absorption of 
bacterial lipo polysaccharides raises immune activation,26,27 
and co-trimoxazole use at ART initiation could increase 
and accelerate reductions in immune activation, especially 
before ART has itself aﬀ ected immune activation. In a 
few small studies from resource-limited settings, 
investigators have reported high pre-ART immune 
activation, which then decreases only gradually during 
the ﬁ rst 48 weeks of treatment.28–30 Peripheral blood 
mononuclear cells were not stored in DART, so we cannot 
investigate this immune activation hypothesis further. 
Mortality in patients accessing ART programmes in 
sub-Saharan Africa is very high in the ﬁ rst year on 
treatment, with 8–26% of patients dying,31–33 most in the 
ﬁ rst 3–6 months. Even when baseline immunodeﬁ ciency 
is allowed for, early mortality is several times higher in 
resource-limited settings than it is in high-income 
settings.34 Although co-trimoxazole prophylaxis is recom-
mended by WHO for symptomatic adults initiating ART 
in resource-limited settings, practice is variable and 
prophylaxis is often omitted. With no data from Africa, 
WHO recommendations were based on extrapolation 
from US studies, and many physicians have judged that 
co-trimoxazole would both be of little beneﬁ t and have the 
potential to compromise adherence. In DART, adherence 
was high, and concerns that initiation of both co-
trimoxazole and ART together might lead to unacceptably 
high rates of toxic eﬀ ects are not substantiated by our data. 
The mortality beneﬁ ts, safety, and tolerability, together 
with the low cost and simplicity of implementation, 
suggest that co-trimoxazole prophylaxis is cost eﬀ ective 
and has a substantial public health eﬀ ect. Our results 
reinforce WHO guidelines and provide strong motivation 
for provision of co-trimoxazole prophylaxis for at least 
72 weeks to all adults starting combination ART in Africa. 
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